As AI rapidly reshapes the evidence landscape, health technology assessment (HTA) bodies are beginning to define clear expectations for its use in submissions. At CapeStart, we work closely with life sciences clients navigating these changes—especially those integrating GenAI into literature reviews, RWE generation, economic modeling, Joint Clinical Assessment (JCA) support, Clinical Evaluation Reports (CERs), Patient…
The rise of generative AI (GenAI) is transforming how life sciences organizations approach evidence synthesis, regulatory submissions, and market access activities. As literature review workflows become more complex—and timelines more compressed—life science professionals are increasingly turning to GenAI-enabled platforms to streamline systematic literature reviews (SLRs), reduce manual burden, and scale evidence synthesis.
However, evaluating…
